SI1971329T1 - Triazine derivatives for use in the treatment of cicatrization - Google Patents

Triazine derivatives for use in the treatment of cicatrization Download PDF

Info

Publication number
SI1971329T1
SI1971329T1 SI200632225T SI200632225T SI1971329T1 SI 1971329 T1 SI1971329 T1 SI 1971329T1 SI 200632225 T SI200632225 T SI 200632225T SI 200632225 T SI200632225 T SI 200632225T SI 1971329 T1 SI1971329 T1 SI 1971329T1
Authority
SI
Slovenia
Prior art keywords
alkoxy
alkyl
aryl
optionally substituted
halogen
Prior art date
Application number
SI200632225T
Other languages
English (en)
Slovenian (sl)
Inventor
Gerard Moinet
Daniel Cravo
Original Assignee
Poxel Sas Immeuble Le Sunway
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Poxel Sas Immeuble Le Sunway filed Critical Poxel Sas Immeuble Le Sunway
Publication of SI1971329T1 publication Critical patent/SI1971329T1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
SI200632225T 2006-01-13 2006-12-18 Triazine derivatives for use in the treatment of cicatrization SI1971329T1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0600347A FR2896161B1 (fr) 2006-01-13 2006-01-13 Utilisation de derives de triazines pour fabriquer un medicament ayant un effet cicatrisant ou angiogenique.
EP06829704.3A EP1971329B1 (en) 2006-01-13 2006-12-18 Triazine derivatives for use in a cicatrising treatment
PCT/EP2006/012183 WO2007079915A2 (en) 2006-01-13 2006-12-18 Use of triazine derivatives for the manufacture of a medicament having a cicatrising or angiogenic effect

Publications (1)

Publication Number Publication Date
SI1971329T1 true SI1971329T1 (en) 2018-03-30

Family

ID=36658622

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200632225T SI1971329T1 (en) 2006-01-13 2006-12-18 Triazine derivatives for use in the treatment of cicatrization

Country Status (22)

Country Link
US (1) US8217040B2 (cg-RX-API-DMAC10.html)
EP (1) EP1971329B1 (cg-RX-API-DMAC10.html)
JP (1) JP2009523140A (cg-RX-API-DMAC10.html)
KR (1) KR101482686B1 (cg-RX-API-DMAC10.html)
CN (1) CN101355931A (cg-RX-API-DMAC10.html)
AR (1) AR059034A1 (cg-RX-API-DMAC10.html)
AU (1) AU2006334732B2 (cg-RX-API-DMAC10.html)
BR (1) BRPI0620983B8 (cg-RX-API-DMAC10.html)
CA (1) CA2636838C (cg-RX-API-DMAC10.html)
CY (1) CY1119872T1 (cg-RX-API-DMAC10.html)
DK (1) DK1971329T3 (cg-RX-API-DMAC10.html)
EA (1) EA016127B1 (cg-RX-API-DMAC10.html)
ES (1) ES2647912T3 (cg-RX-API-DMAC10.html)
FR (1) FR2896161B1 (cg-RX-API-DMAC10.html)
HU (1) HUE037217T2 (cg-RX-API-DMAC10.html)
IL (1) IL192595A (cg-RX-API-DMAC10.html)
LT (1) LT1971329T (cg-RX-API-DMAC10.html)
PL (1) PL1971329T3 (cg-RX-API-DMAC10.html)
PT (1) PT1971329T (cg-RX-API-DMAC10.html)
SI (1) SI1971329T1 (cg-RX-API-DMAC10.html)
WO (1) WO2007079915A2 (cg-RX-API-DMAC10.html)
ZA (1) ZA200806946B (cg-RX-API-DMAC10.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2948027A1 (fr) * 2009-07-17 2011-01-21 Merck Sante Sas Derives amines de dihydro-1,3,5-triazine pour leur utilisation dans le traitement des maladies associees a une ischemie et/ou une reperfusion
EP3691650A1 (en) 2017-10-02 2020-08-12 Poxel Methods of treating heart failure with preserved ejection fraction
MY203360A (en) 2018-06-06 2024-06-26 Metavant Sciences Gmbh Methods of treating subjects having diabetes with chronic kidney disease
CA3103324A1 (en) 2018-06-14 2019-12-19 Poxel Film-coated tablet comprising a triazine derivative for use in the treatment of diabetes
EP4014962A1 (de) * 2020-12-16 2022-06-22 Novigo GmbH & Co. KG Zusammensetzung mit osmotisch wirksamer substanz und verwendung der zusammensetzung
FR3149774B1 (fr) * 2024-01-11 2025-06-20 Fabre Pierre Dermo Cosmetique 5,6,5’,6’-tétraphényl-3,3’-(1,4-phénylène)-bis[1,2,4]triazine pour améliorer l’aspect des cicatrices et/ou réduire les marques cicatricielles

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6150362A (en) * 1997-12-12 2000-11-21 Henkin; Jack Triazine angiogenesis inhibitors
CN1290264A (zh) * 1997-12-12 2001-04-04 艾博特公司 三嗪类血管生成抑制剂
FR2804113B1 (fr) * 2000-01-26 2004-06-18 Lipha Derives animes de dihydro-1,3,5-triazine et leurs applications en therapeutique
US7622469B2 (en) * 2002-12-17 2009-11-24 Hamari Chemicals, Ltd. 2,4-diamino-1,3,5-triazine derivatives
FR2853650B1 (fr) * 2003-04-10 2006-07-07 Merck Sante Sas Procede de dedoublement d'amines utiles pour le traitement de desordres associes au syndrome d'insulino-resistance

Also Published As

Publication number Publication date
KR101482686B1 (ko) 2015-01-14
PT1971329T (pt) 2017-11-24
IL192595A (en) 2013-04-30
BRPI0620983A2 (pt) 2011-11-29
US8217040B2 (en) 2012-07-10
AU2006334732B2 (en) 2012-05-17
CA2636838A1 (en) 2007-07-19
EA016127B1 (ru) 2012-02-28
CY1119872T1 (el) 2018-06-27
BRPI0620983B8 (pt) 2021-05-25
LT1971329T (lt) 2018-01-25
CN101355931A (zh) 2009-01-28
FR2896161B1 (fr) 2008-04-04
EA200801678A1 (ru) 2008-12-30
WO2007079915A2 (en) 2007-07-19
HUE037217T2 (hu) 2018-08-28
DK1971329T3 (en) 2017-12-04
AR059034A1 (es) 2008-03-12
IL192595A0 (en) 2009-02-11
AU2006334732A1 (en) 2007-07-19
PL1971329T3 (pl) 2018-03-30
EP1971329A2 (en) 2008-09-24
EP1971329B1 (en) 2017-10-11
US20100168115A1 (en) 2010-07-01
KR20080088629A (ko) 2008-10-02
FR2896161A1 (fr) 2007-07-20
CA2636838C (en) 2015-05-05
WO2007079915A3 (en) 2007-08-30
ZA200806946B (en) 2009-11-25
JP2009523140A (ja) 2009-06-18
ES2647912T3 (es) 2017-12-27
BRPI0620983B1 (pt) 2019-09-17

Similar Documents

Publication Publication Date Title
AU2018256624A1 (en) JAK2 and ALK2 inhibitors and methods for their use
PH12022550783A1 (en) Antiviral heterocyclic compounds
PE20070527A1 (es) Derivados de espirocromanona como agentes inhibidores de la acetil coenzima a carboxilasa
CA2551178A1 (en) Polycyclic agents for the treatment of respiratory syncytial virus infections
TW200630344A (en) Tetracyclic indole derivatives as antiviral agents
NO991423D0 (no) Qinolinderivater som inhiberer effekten av vekstfaktorer som VEGF
SI3002283T1 (en) Thiazole derivatives
MX2011012627A (es) Derivados aminobutiricos sustituidos como inhibidores de nepralisina.
RU2011138962A (ru) Производные 4-изопропилфенилглюцита в качестве ингибиторов sglt1
WO2008114819A1 (ja) 新規アデニン化合物
PT1119567E (pt) Derivados de quinazolina
WO2010068760A3 (en) New 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication
TW200719886A (en) Dihydrobenzofuran derivatives and uses thereof
HRP20170104T1 (hr) Derivati tipa azaindazola ili diazaindazola za liječenje boli
ECSP045073A (es) Nuevos derivados de piperazina
ECSP099767A (es) Derivados de n' - (fenil) -n- (morfolin-4-il-piridin-2-il) -pirimidina-2, 4-diamina como inhibidores de quinasas ephb4 para el tratamiento de afecciones proliferativas
FI3909584T3 (fi) Pyrimidiiniyhdiste tai sen suola
MX391096B (es) Formulación liposomal.
AR059739A1 (es) Formulaciones y procesos para tabletas
TW200639159A (en) Treatment of pain
NO20065078L (no) Inhaleringspulver formuleringer inneholdende enantiomerisk rene beta-agonister.
JP2009523142A5 (cg-RX-API-DMAC10.html)
JP2014530882A5 (cg-RX-API-DMAC10.html)
JP2009523139A5 (cg-RX-API-DMAC10.html)
DE602005018972D1 (de) 5,6-dimethylthienoä2,3-diüpyrimidinderivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzung für die bekämpfung von viren